Lexicon Pharmaceuticals Restructures, Cuts 60% of Staff After FDA Flags Zynquista Deficiencies
Key Insights
Lexicon Pharmaceuticals will lay off 60% of its workforce and disband its sales team to save $100 million, pivoting to focus on its research pipeline.
The restructuring follows an FDA letter citing deficiencies in Lexicon's approval application for its diabetes (search) drug, Zynquista (sotagliflozin).
Lexicon will halt promotion of Inpefa, another sotagliflozin-containing drug, while continuing its Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy (search).
Lexicon Pharmaceuticals is undergoing a significant restructuring, including laying off 60% of its workforce and eliminating its commercial operations, after receiving a letter from the Food and Drug Administration (FDA) citing “deficiencies” in its approval application for Zynquista (sotagliflozin), a diabetes (search) drug. The company aims to save $100 million in operating costs through this move, shifting its focus to its research pipeline.
The FDA's concerns arose during the review of sotagliflozin for a specific group of people with Type 1 diabetes (search) and chronic kidney disease (search), with an advisory committee already suggesting that the drug's benefits did not outweigh its risks in late October. The agency indicated that the application's shortcomings prevented discussions about potential labeling or post-marketing requirements.
Facing these regulatory hurdles, Lexicon has decided to discontinue promotion of Inpefa, another drug containing sotagliflozin used to reduce cardiovascular complications in patients with heart failure (search) or Type 2 diabetes (search), chronic kidney disease (search), and other risk factors. While Lexicon will continue to manufacture and make Inpefa available, the company is transitioning to a “clinical development-focused” model.
Pipeline Focus
Lexicon will now prioritize its research pipeline, which includes a drug in Phase 2 testing for diabetic peripheral neuropathic pain (search) and a preclinical obesity (search) therapy. The company is also continuing a Phase 3 study of sotagliflozin in people with hypertrophic cardiomyopathy (search), exploring its potential in other therapeutic areas.
This restructuring builds upon an earlier cost-cutting initiative that involved layoffs for 75 employees, further streamlining the company's operations. The strategic shift reflects the challenges Lexicon faces in the diabetes (search) market and its renewed commitment to advancing its clinical programs.